New leadership at SynOx Therapeutics

Wednesday 28 July 2021
SynOx Therapeutics Ltd
Appointee name
Ray Barlow and Ton Logtenberg


Ireland-based SynOx Therapeutics Ltd has appointed a new chief executive and non-executive chairman as it prepares to bring the cancer therapy, emactuzumab, into a registrational trial in the US and EU. Ray Barlow has become CEO and Ton Logtenberg, chairman, bringing with them decades of scientific and business experience in the biopharmaceutical industry.

Professor Logtenberg was co-founder and chief scientific officer of Crucell NV, the Netherlands-based vaccine company acquired by Johnson & Johnson Inc in 2011. He also founded and led Merus NV, a developer of bispecific antibodies for cancer.

Dr Barlow has held leadership positions at AstraZeneca Plc, Crucell and Amgen Inc. More recently he was CEO of e-Therapeutics Plc and chief business officer at Kiadis Pharma NV, up to its acquisition by Sanofi in April 2021.

SnyOx announced the appointments on 27 July 2021.

Copyright 2021 Evernow Publishing Ltd